Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00PXO
|
|||
| Former ID |
DIB018909
|
|||
| Drug Name |
CGK733
|
|||
| Synonyms |
CGK733; 905973-89-9; CGK 733; CGK-733; 2,2-Diphenyl-N-(2,2,2-trichloro-1-(3-(4-fluoro-3-nitrophenyl)thioureido)ethyl)acetamide; CHEMBL1221601; 2,2-Diphenyl-n-(2,2,2-trichloro-1-[3-(4-fluoro-3-nitrophenyl)thioureido]ethyl)acetamide; UNII-L3DGZ99QYM; 2,2-diphenyl-N-(2,2,2-trichloro-1-{[(4-fluoro-3-nitrophenyl)carbamothioyl]amino}ethyl)acetamide; 2,2-diphenyl-N-[2,2,2-trichloro-1-[(4-fluoro-3-nitrophenyl)carbamothioylamino]ethyl]acetamide; L3DGZ99QYM
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C23H18Cl3FN4O3S
|
|||
| Canonical SMILES |
C1=CC=C(C=C1)C(C2=CC=CC=C2)C(=O)NC(C(Cl)(Cl)Cl)NC(=S)NC3=CC(=C(C=C3)F)[N+](=O)[O-]
|
|||
| InChI |
1S/C23H18Cl3FN4O3S/c24-23(25,26)21(30-22(35)28-16-11-12-17(27)18(13-16)31(33)34)29-20(32)19(14-7-3-1-4-8-14)15-9-5-2-6-10-15/h1-13,19,21H,(H,29,32)(H2,28,30,35)
|
|||
| InChIKey |
HLCDNLNLQNYZTK-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 905973-89-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
11114625, 11164639, 22391633, 24640128, 24724454, 26758161, 29203588, 29217536, 43224989, 50111704, 50554646, 53800986, 57371156, 85083168, 85787673, 98629307, 99302614, 104242356, 114638881, 117645996, 125503183, 134964067, 135348704, 135698776, 162023471, 162124860, 162250092, 163620943, 163686265, 163688667, 164045287, 172913233, 175607451, 178102552, 179694519, 184813120, 208265192, 208265505, 223377718, 223404308, 228140564, 241376046, 242060234, 245597933, 251971091, 252156674, 252215124, 252300148, 252441266, 252451362
|
|||
| ChEBI ID |
CHEBI:91739
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | ATM serine/threonine kinase (ATM) | Target Info | Inhibitor | [2] |
| Serine/threonine-protein kinase ATR (FRP1) | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Fanconi anemia pathway | |||
| Cell cycle | ||||
| p53 signaling pathway | ||||
| HTLV-I infection | ||||
| Panther Pathway | p53 pathway | |||
| p53 pathway feedback loops 2 | ||||
| Pathway Interaction Database | Fanconi anemia pathway | |||
| ATR signaling pathway | ||||
| Signaling events mediated by TCPTP | ||||
| Circadian rhythm pathway | ||||
| BARD1 signaling events | ||||
| p53 pathway | ||||
| Reactome | Meiotic synapsis | |||
| Activation of ATR in response to replication stress | ||||
| Regulation of HSF1-mediated heat shock response | ||||
| HDR through Single Strand Annealing (SSA) | ||||
| Processing of DNA double-strand break ends | ||||
| Presynaptic phase of homologous DNA pairing and strand exchange | ||||
| G2/M DNA damage checkpoint | ||||
| WikiPathways | DNA Damage Response | |||
| Meiotic Synapsis | ||||
| Prostate Cancer | ||||
| Integrated Breast Cancer Pathway | ||||
| Integrated Cancer pathway | ||||
| Cell Cycle | ||||
| Cell Cycle Checkpoints | ||||
| miRNA Regulation of DNA Damage Response | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5929). | |||
| REF 2 | Small molecule-based reversible reprogramming of cellular lifespan. Nat Chem Biol. 2006 Jul;2(7):369-74. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.